Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
Craig M. McDonald(University of California Davis Medical Center), Francina Munell(Vall d'Hebron Institut de Recerca), Michela Guglieri(Muscular Dystrophy UK), Mercedes López Lobato, John F. Brandsema, Valeria Sansone(University of Milan), Sara Cazzaniga(Italfarmaco (Italy)), Krista Vandenborne(University of Florida), Mariacristina Scoto(University College London), Dragana Vučinić(Center for Children), Nuria Muelas(Hospital Universitari i Politècnic La Fe), Eugenio Mercuri(Università Cattolica del Sacro Cuore), Federica Alessi(Policlinico Umberto I), Yann Péréon(European Organisation for Rare Diseases), Gyula Acsádi(Connecticut Children's Medical Center), Erika Finanger, Richard S. Finkel(St. Jude Children's Research Hospital), Tracey Willis(Robert Jones and Agnes Hunt Orthopaedic Hospital), Yoram Nevo(Tel Aviv University), P. Bettica(Italfarmaco (Italy)), H. Phan(Rare Disease Therapeutics (United States)), Claudio Bruno(Istituto Giannina Gaslini), Amy Harper, Silvia Montrasio(Italfarmaco (Italy)), Riccardo Masson, the Givinostat Study 51 Investigators
Cited by 12
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy
|Nature Genetics|2001|618
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565